Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT).
Results of 3000 patients transplanted for chronic myeloid leukemia in Europeere used to assess outcome and main risk factors for survival (SURV), leukemia free survival (LFS), relapse incidence (RI) and transplant related mortality (TRM). More than one third (39%) of all patients are alive at + 10 years. SURV at 10 years is better for patients transplanted in first chronic phase (49%) than in accelerated phase (19%) or blast crisis (0%) due to both decreased TRM (41% versus 67% versus -) and RI (35% versus 51% versus -). For those patients transplanted in first chronic phase from an HLA-identical sibling donor with non-T-cell depleted bone marrow, modern conditioning and GVHD prevention method, median SURV has not been reached at +10 years and exceeds 55%. Other risk factors are discussed.
Gratwohl
A
A
Department of Internal Medicine and Research, Kantonsspital Basel, Switzerland.
Hermans
J
J
D000208:Acute Disease; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology / Q000401:mortality; D005060:Europe / Q000453:epidemiology; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012307:Risk Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous